Petros Pharmaceuticals, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
Petros Pharmaceuticals, Inc. (PTPI) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $33.40 per share for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-15.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2024-04-01
- Petros Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $33.40.
- Petros Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2022 was $32.10, a 93.76% decline from fiscal 2021.
- Petros Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2021 was $514.30.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2023-09-30 | $33.40 10-Q · filed 2023-11-15 | ||||
| 2023-06-30 | $33.40 10-Q · filed 2023-08-14 | ||||
| 2023-03-31 | $33.40 10-Q · filed 2023-05-15 | ||||
| 2022-12-31 | $32.10 10-K · filed 2024-04-01 | ||||
| 2021-12-31 | $514.30 10-K · filed 2023-03-31 | $51.43 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |